XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.1
License and Collaboration Agreements - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Revenue $ 124,926 $ 100,448
Collaborative Arrangement    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Payment for option exercise $ 237,000  
Stock options exercised or expired 0  
Development Milestone and Upfront Fee Recognized as Research and Development Expense $ 14,000 8,500
Collaborative Arrangement | Maximum [Member]    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Contingent research milestone payments 14,000  
Development Milestone and Settlement Upfront Fee Recognized as Research and Development Expense 3,900,000  
Collaborative Arrangement | Roche    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Revenue 22,000 13,200
Deferred Revenue 730,700  
Deferred Revenue, Current 89,200  
Deferred Revenue Separate Material Options Right 485,000  
Research and development expense 13,400 $ 16,400
Collaboration Receivable $ 15,100